These studies, therefore, conclude that up-regulation of miR-15a, miR-16 sensitizes breast cancer to chemotherapeutic drug doxorubicin by targeting BMI1 and this approach might be the potential strategy for the treatment of breast cancer. This evidence concerns the gene BMI1 and breast cancer.